Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

In vitro selection and characterization of VX-478 resistant HIV-1 variants.

Pazhanisamy S, Partaledis JA, Rao BG, Livingston DJ.

Adv Exp Med Biol. 1998;436:75-83. Review.

PMID:
9561202
2.

Weak binding of VX-478 to human plasma proteins and implications for anti-human immunodeficiency virus therapy.

Livington DJ, Pazhanisamy S, Porter DJ, Partaledis JA, Tung RD, Painter GR.

J Infect Dis. 1995 Nov;172(5):1238-45.

PMID:
7594659
3.

In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease.

Partaledis JA, Yamaguchi K, Tisdale M, Blair EE, Falcione C, Maschera B, Myers RE, Pazhanisamy S, Futer O, Cullinan AB, et al.

J Virol. 1995 Sep;69(9):5228-35.

5.

Saccharomyces cerevisiae contains a homolog of human FKBP-13, a membrane-associated FK506/rapamycin binding protein.

Partaledis JA, Fleming MA, Harding MW, Berlin V.

Yeast. 1992 Sep;8(9):815. No abstract available.

PMID:
1441758
6.

Saccharomyces cerevisiae contains a homolog of human FKBP-13, a membrane-associated FK506/rapamycin binding protein.

Partaledis JA, Fleming MA, Harding MW, Berlin V.

Yeast. 1992 Aug;8(8):673-80. Erratum in: Yeast. 1992 Sep;8(9):815.

PMID:
1279908

Supplemental Content

Loading ...
Support Center